share_log

T2 Biosystems | 4: Statement of changes in beneficial ownership of securities

T2 Biosystems | 4:持股變動聲明

美股sec公告 ·  02/17 06:22
牛牛AI助理已提取核心訊息
CR Group L.P., a significant stakeholder in T2 Biosystems, Inc. [TTOO], reported acquiring additional shares of the company's common stock on February 14, 2024. The transactions were made indirectly through two entities. CRG Partners III (Cayman) Lev AIV I L.P. acquired 335,947 shares, while CRG Partners III Parallel Fund B LP added 488,273 shares to their holdings. Following these transactions, the total number of shares held by CR Group L.P. in T2 Biosystems amounts to 824,220. The acquisitions were made indirectly, signifying an increase in CR Group L.P.'s investment in the medical diagnostic company.
CR Group L.P., a significant stakeholder in T2 Biosystems, Inc. [TTOO], reported acquiring additional shares of the company's common stock on February 14, 2024. The transactions were made indirectly through two entities. CRG Partners III (Cayman) Lev AIV I L.P. acquired 335,947 shares, while CRG Partners III Parallel Fund B LP added 488,273 shares to their holdings. Following these transactions, the total number of shares held by CR Group L.P. in T2 Biosystems amounts to 824,220. The acquisitions were made indirectly, signifying an increase in CR Group L.P.'s investment in the medical diagnostic company.
T2 Biosystems, Inc. [TTOO] 的重要利益相關者CR集團有限責任公司報告稱,於2024年2月14日收購了該公司普通股的額外股份。這些交易是通過兩個實體間接進行的。CRG Partners III(開曼)Lev AIV I L.P. 收購了335,947股股票,而CRG Partners III平行基金B LP則增加了488,273股股票。這些交易之後,CR集團有限責任公司在T2 Biosystems中持有的股份總數爲824,220股。這些收購是間接進行的,這表明CR集團有限責任公司的增加。”對醫療診斷公司的投資。
T2 Biosystems, Inc. [TTOO] 的重要利益相關者CR集團有限責任公司報告稱,於2024年2月14日收購了該公司普通股的額外股份。這些交易是通過兩個實體間接進行的。CRG Partners III(開曼)Lev AIV I L.P. 收購了335,947股股票,而CRG Partners III平行基金B LP則增加了488,273股股票。這些交易之後,CR集團有限責任公司在T2 Biosystems中持有的股份總數爲824,220股。這些收購是間接進行的,這表明CR集團有限責任公司的增加。”對醫療診斷公司的投資。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。